LIFECORE BIOMEDICAL INC (LFCR) Stock Fundamental Analysis
USA - NASDAQ:LFCR - US5147661046 - Common Stock
6.61 USD
-0.16 (-2.36%)
Overall LFCR gets a fundamental rating of 2 out of 10. We evaluated LFCR against 58 industry peers in the Life Sciences Tools & Services industry. LFCR has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LFCR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
LFCR had negative earnings in the past year.
LFCR had a negative operating cash flow in the past year.
LFCR had negative earnings in 4 of the past 5 years.
LFCR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -18.53%, LFCR is in line with its industry, outperforming 41.38% of the companies in the same industry.
LFCR has a Return On Equity of -93.52%. This is in the lower half of the industry: LFCR underperforms 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.53% | ||
| ROE | -93.52% | ||
| ROIC | N/A |
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LFCR has a Gross Margin of 31.27%. This is in the lower half of the industry: LFCR underperforms 68.97% of its industry peers.
In the last couple of years the Gross Margin of LFCR has grown nicely.
LFCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
2. Health
2.1 Basic Checks
LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFCR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LFCR has been increased compared to 5 years ago.
The debt/assets ratio for LFCR is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.29, we must say that LFCR is in the distress zone and has some risk of bankruptcy.
LFCR's Altman-Z score of 0.29 is on the low side compared to the rest of the industry. LFCR is outperformed by 70.69% of its industry peers.
LFCR has a Debt/Equity ratio of 2.68. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of LFCR (2.68) is worse than 87.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.68 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.29 |
ROIC/WACCN/A
WACC9.1%
2.3 Liquidity
A Current Ratio of 2.84 indicates that LFCR has no problem at all paying its short term obligations.
LFCR has a Current ratio (2.84) which is in line with its industry peers.
LFCR has a Quick Ratio of 1.77. This is a normal value and indicates that LFCR is financially healthy and should not expect problems in meeting its short term obligations.
LFCR has a Quick ratio (1.77) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.84 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
The earnings per share for LFCR have decreased strongly by -669.18% in the last year.
Looking at the last year, LFCR shows a small growth in Revenue. The Revenue has grown by 0.47% in the last year.
Measured over the past years, LFCR shows a decrease in Revenue. The Revenue has been decreasing by -4.25% on average per year.
EPS 1Y (TTM)-669.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
Revenue 1Y (TTM)0.47%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%-3.81%
3.2 Future
LFCR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.41% yearly.
The Revenue is expected to grow by 21.24% on average over the next years. This is a very strong growth
EPS Next Y41.64%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue Next Year3.52%
Revenue Next 2Y7.18%
Revenue Next 3Y11.96%
Revenue Next 5Y21.24%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LFCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LFCR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LFCR's earnings are expected to grow with 23.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.63%
EPS Next 3Y23.41%
5. Dividend
5.1 Amount
No dividends for LFCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:LFCR (11/6/2025, 3:27:33 PM)
6.61
-0.16 (-2.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners76.4%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner Change6.07%
Market Cap247.68M
Revenue(TTM)128.87M
Net Income(TTM)-44359000
Analysts80
Price Target10.2 (54.31%)
Short Float %7.48%
Short Ratio16.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-84.55%
Min EPS beat(2)-207.19%
Max EPS beat(2)38.08%
EPS beat(4)2
Avg EPS beat(4)-39.23%
Min EPS beat(4)-207.19%
Max EPS beat(4)38.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.38%
Min Revenue beat(2)1.03%
Max Revenue beat(2)3.72%
Revenue beat(4)4
Avg Revenue beat(4)4.13%
Min Revenue beat(4)1.03%
Max Revenue beat(4)7.32%
Revenue beat(8)5
Avg Revenue beat(8)2.28%
Revenue beat(12)6
Avg Revenue beat(12)-5.39%
Revenue beat(16)7
Avg Revenue beat(16)-14.35%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.81%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)4%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.92 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.22 | ||
| P/tB | 8.44 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.27
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS3.44
BVpS1.27
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.53% | ||
| ROE | -93.52% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.27% | ||
| FCFM | N/A |
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
F-Score3
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.68 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 167.12% | ||
| Cap/Sales | 10.41% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.84 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | 0.29 |
F-Score3
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)177.04%
Cap/Depr(5y)161.61%
Cap/Sales(3y)15.06%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-669.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
EPS Next Y41.64%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue 1Y (TTM)0.47%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%-3.81%
Revenue Next Year3.52%
Revenue Next 2Y7.18%
Revenue Next 3Y11.96%
Revenue Next 5Y21.24%
EBIT growth 1Y-17.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year656.28%
EBIT Next 3Y130.51%
EBIT Next 5YN/A
FCF growth 1Y24.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.07%
OCF growth 3YN/A
OCF growth 5YN/A
LIFECORE BIOMEDICAL INC / LFCR FAQ
What is the fundamental rating for LFCR stock?
ChartMill assigns a fundamental rating of 2 / 10 to LFCR.
What is the valuation status of LIFECORE BIOMEDICAL INC (LFCR) stock?
ChartMill assigns a valuation rating of 1 / 10 to LIFECORE BIOMEDICAL INC (LFCR). This can be considered as Overvalued.
Can you provide the profitability details for LIFECORE BIOMEDICAL INC?
LIFECORE BIOMEDICAL INC (LFCR) has a profitability rating of 1 / 10.
What is the expected EPS growth for LIFECORE BIOMEDICAL INC (LFCR) stock?
The Earnings per Share (EPS) of LIFECORE BIOMEDICAL INC (LFCR) is expected to grow by 41.64% in the next year.